Chisingaperi Hepatitis B: New Clinical Muedzo

Brii Biosciences Limited, kambani yenyika dzakawanda inogadzira marapirwo matsva ezvirwere zvine zvakakosha zvisingaite zvekurapa uye mitoro mikuru yehutano hweveruzhinji, yakapa murwere wekutanga muChikamu 2a/2b chekiriniki yekuyedza BRII-179 (VBI-2601) muvarwere vane chirwere chisingaperi chehepatitis B (HBV). Vanhu vanosvika mamiriyoni mazana maviri nemakumi mapfumbamwe pasi rose vari kurarama nechirwere cheHBV chisingaperi, uye vanhu vangangosvika 290 800,000 vanofa gore rega rega nekuda kwezvirwere zvakaita seHBV-related cirrhosis, kusashanda kwechiropa, uye gomarara rine hukama.           

"BRII-179 ine mukana wekupwanya kushivirira kwekudzivirira uye kudzoreredza kana kuwedzera adaptive T cell uye antibody mhinduro kune HBV pamusoro maantigen. Izvi zvinogadzira mhinduro yakasimba yekudzivirira zvirwere kuHBV uye kugadzira mukana wekuwana mushonga wechirwere chisingaperi cheHBV," akadaro Li Yan, MD, Ph.D., mukuru wezvekurapa kuBrii Bio. “Varwere veHBV vane chirwere cheHBV parizvino vanongokwanisa kuwana marapiro anoita kuti pave nenhamba imwe chete yekurapa. Tinotarisira kushanda nevaongorori vedu kuChina kuona kuchengetedzwa uye kukanganisa kweBRII-179 mukusimbisazve HBV-chaiyo inogadzirisa immune immune muhuwandu hwevarwere, iyo inogona kududzira muhuwandu hwepamusoro hwekurapa.

BRII-179 (VBI-2601) ibhuku remubatanidzwa, protein-based HBV immunotherapeutic mumiriri inoratidzira Pre-S1, Pre-S2, uye S HBV epamusoro maantigens, uye yakagadzirirwa kukurudzira yakagadziridzwa B-cell uye T-cell kusadzivirirwa. . BRII-179 (VBI-2601) inovaka pane matatu-antigen conformation yeVBI Vaccines' prophylactic HBV vaccine, iyo yakatenderwa kuUS pasi pezita rePreHevbrio™ [Hepatitis B Vaccine (Recombinant)].

Iyi Phase 2 kuyedza yeBRII-179 ndeye kaviri-mapofu, randomized, placebo-inodzorwa, parallel-boka kudzidza kuongorora kliniki mhedzisiro yekuwedzera BRII-179 (VBI-2601) kune iripo PEG-IFN-α uye nucleos (t. ) ide reverse transcriptase inhibitor (NrtI) yakajairwa-ye-kutarisira kurapwa mune vasiri-cirrhotic vasingaperi HBV varwere. Varwere vari kutora chikamu muchidzidzo vakasangana neyakatsanangurwa maitiro emhinduro dzisina kukwana kune inoenderera mberi PEG-IFN-α uye NrtI kurapwa. Dare rakazvimirira reData uye Chengetedzo Monitoring Board richaongorora kuchengetedzwa kwemurwere uye dhata rekugona kurapwa kwechidzidzo ichi.

Chikamu 2a:

• Chikamu 2a chikamu chekudzidza chichagadzirisa kushanda uye kuchengeteka kweBRII-179 (VBI-2601) therapy mune vanenge 120 varwere pamwe chete nePEG-IFN-α + Nrtl therapy.

• Mhedziso yekutanga yeChikamu 2a ndiyo yezana yevarwere vane HBsAg kurasikirwa pakupera kwekurapa.

Chikamu 2b:

• MuChikamu 2b, chidzidzo chacho chichawedzera kusvika kuvarwere ve480 kuti vaongorore chikamu chevarwere vanowana kurapwa kwebasa mushure mekugamuchira BRII-179 (VBI-2601) therapy pamwe chete nePEG-IFN-α + NrtI.

• Mhedziso yekutanga yeChikamu 2b chikamu chevarwere vanowana HBsAg yakaramba uye HBV DNA kurasikirwa.